via Monash University
A multi-disciplinary project driven by EMBL Australia researchers at Monash University and Harvard University has found a way to make antibiotics more effective against antibiotic-resistant bacteria – also known as ‘superbugs.
Antimicrobial resistance to superbugs has been evolving and is one of the top 10 global public health threats facing humanity, according to the World Health Organization.
This new research will provide a pathway to increasing the effectiveness of antibiotics, without clinicians having to resort to risky strategies of giving patients higher doses or relying on the discovery of new types of antibiotics.
During a bacterial infection, the body uses molecules called chemoattractants to recruit neutrophils to the site of the infection. Neutrophils are immune cells with the ability to encapsulate and kill dangerous bacteria, critical to the immune response. Researchers attached a chemoattractant to an antibiotic, enabling them to enhance the recruitment of immune cells and improve their killing ability.
The findings have now been published in Nature Communications.
“When looking at how our immune system can fight bacteria there are two important aspects we look at. The first is our ability to entrap bacterial cells and kill them. The second is the signals – the chemoattractants – calling for more neutrophils, white blood cells which lead the immune system’s response to resolve infection,” said Dr Jennifer Payne, the lead researcher from EMBL Australia and the Monash Biomedicine Discovery Institute.
The researchers linked a chemoattractant known as formyl peptide to vancomycin, a commonly used antibiotic that binds to the surface of the bacteria, and performed their studies on golden staph infections, one of the more problematic antibiotic-resistant bacteria.
“We’ve been working on using dual-function antibiotic-chemoattractant ‘hybrids’, which improve the recruitment of neutrophils and increase the engulfing and killing of the bacteria,” said Dr Payne.
“By stimulating our powerful immune system in this way with the immunotherapeutic antibiotic, we’ve shown in mouse models that the treatment is 2-fold more effective than just using the antibiotic alone at one-fifth lower dose,” said Associate Professor Max Cryle, an EMBL Australia Group Leader at the Monash Biomedicine Discovery Institute.
“This very promising new avenue of research is bringing a lot of potential benefits to the ever-increasing threat of drug-resistant superbugs,” said Associate Professor Cryle.
Instrumental to the project was funding from VESKI and Melbourne sister city foundation that took Dr Payne across the world to Boston to learn and carry out microfluidic research learning and collaborating with Associate Professor Daniel Irima, and Dr Felix Ellett, Harvard experts in this field.
“Microfluidics was ground-breaking for this research, as it allowed us to generate an infection-on-a-chip to monitor the recruitment of human immune cells, and observe in real-time how our immunotherapeutic enhances their ability to kill MRSA. Just like what would happen in our body” said Dr Payne,
Partners are being sought to continue this research into clinical trials with the potential of developing a preventative antibiotic strategy in the intensive care environment to protect our most vulnerable.
The work has resulted in a patent covering the immunotherapeutic, with the IP owned by Monash University.
Original Article: Researchers discover a way to increase the effectiveness of antibiotics
More from: Monash University | Harvard University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Antibiotic effectiveness
- FDA Approves New Antibiotic for Uncomplicated UTIs
The US Food and Drug Administration has approved pivmecillinam (Pivya) tablets to treat uncomplicated urinary tract infections in women.
- Vancomycin may be losing effectiveness against C. diff
A new study suggests that the leading antibiotic used to fight Clostridioides difficile, vancomycin, may be losing potency against this killer.
- Common antibiotic Neosporin may shield against viral respiratory infections
A study conducted first in mice and then in human volunteers suggests that a common antibiotic, neomycin, which is the main active ingredient in Neosporin, may help protect against viral respiratory ...
- What to Know About Pivya, the New Antibiotic Treatment for UTIs
The Food and Drug Administration recently approved Pivya (pivmecillinam) to treat uncomplicated UTIs in female adults. Clinical trials show that Pivya is effective and side effects are limited.
- Study: Antibiotic use in patients hospitalized with COVID-19 appears to have no beneficial effect on clinical outcomes
Antibiotic treatment of adults hospitalized with moderate COVID-19 is associated with clinical deterioration, despite the drugs being given to over 40% of patients, according to new research being ...
Go deeper with Google Headlines on:
Antibiotic effectiveness
[google_news title=”” keyword=”antibiotic effectiveness” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Immunotherapeutic antibiotic
- News - rilzabrutinib
French drugmaker Sanofi has unveiled positive results from the Phase III LUNA 3 trial of rilzabrutinib.
- MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
MoonLake Immunotherapeutics ("MoonLake"; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, and Komodo Health today announce a ...
Go deeper with Google Headlines on:
Immunotherapeutic antibiotic
[google_news title=”” keyword=”immunotherapeutic antibiotic” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]